The mammalian target of rapamycin complex 1 (mTORC1) pathway regulates cellular responses to fuel availability. Recent studies have demonstrated that within the central nervous system, and in particular the hypothalamus, mTORC1 represents an essential intracellular target for the actions of hormones and nutrients on food intake and body weight regulation. By being at the crossroads of a nutrient-hormonal signaling network, mTORC1 also controls important functions in peripheral organs, such as muscle oxidative metabolism, white adipose tissue differentiation and b-cell-dependent insulin secretion. Notably, dysregulation of the mTORC1 pathway has been implicated in the development of obesity and obesity-related conditions, such as type 2 diabetes. This manuscript will therefore review recent progress made in understanding the role of the mTORC1 pathway in the regulation of energy balance and peripheral metabolism. Furthermore, we will critically discuss the potential relevance of this intracellular pathway as a therapeutic target for the treatment of metabolic disease.
Introduction
Obesity is generally defined as a condition in which excess body fat has accumulated to an extent that can negatively affect health. Obesity is nowadays a major health problem in developed countries and a growing one in the developing world, becoming one of the most serious public health threats. [1] [2] [3] Indeed, being obese not only increases the risk of developing a number of metabolic disorders, such as type 2 diabetes and hyperlipidemia, but is also associated with the occurrence of cardiovascular disease and some forms of cancers. 4 Moreover, recent studies have shown a correlation among obesity, decline of cognitive functions and development of neurodegenerative disorders, like Alzheimer's. 5, 6 The causes of this alarming obesity epidemic include genetic, socioeconomic and environmental factors. 2 However, despite the human and economic costs of this disease, efficient anti-obesity treatments are currently lacking. Thus, it has become essential to understand the mechanisms that regulate energy balance and peripheral metabolism to identify possible therapeutic targets that will help halt obesity and its disastrous metabolic consequences.
The central nervous system (CNS) is the recognized coordinator of eating behavior, receiving a continuous stream of diverse signals regarding energy status throughout the body, responding to a large variety of external cues related to food availability and palatability, and coordinating the intake of nutrients and their utilization by most tissues.
The hypothalamus is one of the major CNS structures involved in the regulation of energy balance. 8, 9 In recent years, this brain area has indeed received the most attention as being mainly involved in sensing circulating levels of hormones and nutrients and conveying information about the levels of available energy in the organism. 9, 10 However, the neural network guarantying the overall integration and the resulting regulation of energy balance does not solely rely on the hypothalamus. The brainstem, an important relay station for neuroendocrine signals coming from the periphery, as well as several areas of the cortico-limbic system, which convey and integrate the individual's response to food cues, are also critically involved. 11, 12 A growing number of studies has also recently highlighted the important role of intracellular cascades responding to hormones, like insulin and leptin, and nutrients in the regulation of food intake and body weight. In particular, investigations focusing on the so-called 'fuel-sensing' mechanisms, which control cellular responses to fuel availability, have established that these intracellular pathways are also used by hypothalamic circuits to match energy intake and expenditure to the internal fuel levels of the organism. 10, [13] [14] [15] The mammalian target of rapamycin (mTOR) pathway is the latest intracellular fuel-sensing mechanism to be implicated in the regulation of energy balance. [16] [17] [18] mTOR is a highly conserved serine-threonine kinase, which in peripheral cells is known to integrate nutrient signals with hormonal signals to control cell growth and proliferation. 19 Cellular adenosine triphosphate (ATP) levels increase mTOR activity, and the mTOR kinase itself serves as a cellular ATP sensor. 20 mTOR thus works as a critical checkpoint by which cells sense and decode changes in energy status. 19 Indeed, complete loss of mTOR is lethal. 21 Owing to its role in the regulation of cell growth, mTOR has been long investigated as a potential target for the treatment of several forms of cancers. 22 Thanks to these efforts, accumulating evidence has also pointed to an involvement of the pathway in the regulation of essential metabolic processes, spanning from adipogenesis to mitochondrial respiration, and to a potential role in metabolic diseases, including obesity and type 2 diabetes. This review will therefore provide an overview of the most recent advances made in understanding the role of the mTOR pathway in the CNS control of energy balance, as well as in the modulation of peripheral, metabolically relevant functions, such as adipogenesis, lipid biosynthesis and insulin secretion. Furthermore, it will offer some insights on the possible contribution of this pathway to the metabolic dysregulation usually associated with the development of obesity and type 2 diabetes. mTOR pathway: mTORC1 and mTORC2
The target of rapamycin (TOR) kinase was first discovered thanks to genetic screens identifying potential targets for the action of the immunosuppressant rapamycin. 23 The mammalian isoform of TOR (mTOR) is an evolutionarily conserved 289-kDa protein kinase belonging to the phosphatidylinositol kinase-related protein kinases family. 19 mTOR is actually the catalytic subunit of two distinct multiprotein complexes, respectively named mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC1 will be the main subject of this review, because of its recently established role in the regulation of energy balance and peripheral metabolism. mTORC1 includes mTOR, and the proteins mLST8/GbL (mammalian lethal with Sec13 protein/G protein b-subunitlike protein), PRAS40 (proline-rich Akt substrate 40 kDa), Raptor (regulatory associated protein of mTOR) and Deptor (DEP domain-containing mTOR-interacting protein). 24 The function of each of these proteins still remains poorly understood, although Raptor seems to facilitate mTORC1 signaling by recruiting mTORC1 downstream substrates, PRAS40 and Deptor inhibit mTORC1, whereas mLST8/GbL is not essential for mTORC1 activity. 22, 24 mTORC2 includes mTOR, mLST8/GbL, Deptor, Rictor (rapamycin insensitive companion of mTOR), Protor-1 (protein observed with rictor-1) and SIN1 (stress-activated protein kinase-interacting protein). As for mTORC1, Deptor inhibits mTORC2, whereas mLST8/GbL is required for mTORC2 activity. Finally, Rictor and SIN1 stabilize each other, thus building the structural foundation of mTORC2. Rapamycin potently inhibits mTORC1 upon binding to the FKBP12 protein and interacting with the FKBP12 domain of mTOR. In contrast, rapamycin cannot physically interact with and acutely inhibit mTORC2, although prolonged rapamycin treatment can inhibit mTORC2 activity in endothelial cells as well as in adipocyte and myoblast cell lines. 22, 24 mTORC1 has a central role in the control of cell metabolism, proliferation and survival. 19, 24 To be able to carry out its functions, mTORC1 needs to promptly react to mitogens and hormones, as well as to intracellular levels of nutrients and energy (that is, ATP). mTORC1 responds to growth factors through the ERK1/2 (extracellular signalregulated kinase 1/2), the p90 ribosomal S6 kinase 1 (RSK1) and the phosphatidylinositol 3 kinase (PI3K)/Akt pathways (reviewed in Laplante and Sabatini
24
). The latter is among the pathways known to mediate the appetite-suppressing actions of insulin and leptin in the hypothalamus. 25, 26 In the presence of insulin, phosphorylation of Akt leads to inhibition of the tuberous sclerosis protein 2 (TSC2), which downregulates mTORC1 by inhibiting the GTPase Rheb (Ras homolog enriched in the brain). This therefore leads to mTORC1 activation. 19, 22 Importantly, full activation of Akt requires mTORC2 activity. 27 Thus, mTORC2 phosphorylates Akt, whereas Akt phosphorylation leads to mTORC1 activation. mTORC1 in turn phosphorylates its substrates: the S6 kinase 1 (S6K1) and the eukaryotic initiation factor 4E-binding protein (4E-BP1), which regulate protein synthesis. The phosphorylation of S6K1 increases mRNA biogenesis and cap-dependent translation and elongation through the phosphorylation of the S6 ribosomal protein (S6), among other proteins. 24 Whereas the phosphorylation of 4E-BP1 causes eIF4E release, allowing the initiation of translation. 24 Importantly, the phosphorylation status of S6K1, S6 and 4E-BP1 is commonly used as an index of mTORC1 activity. In case of prolonged activation, S6K1 attenuates insulin-mediated PI3K/Akt activity through inhibition of insulin receptor substrate (IRS) proteins. This S6K1-dependent negative feedback loop leads to cellular insulin resistance, as inhibition of IRS proteins causes insulin desensitization. 19, 24 Besides growth factors, mTORC1 activity readily responds to intracellular nutrient levels. Nutrient deprivation directly inhibits the activity of the mTOR kinase, whereas branchedchain amino acid starvation, and in particular the absence of leucine, rapidly dephosphorylates S6K1 and 4E-BP1 in mTORC1 and obesity C Catania et al an mTORC1-dependent manner. 28 Conversely, amino acid availability increases intracellular Ca2 þ levels, which in turn activate mTORC1 signaling by means of Ca2 þ / calmodulin-mediated activation of hVPS34, a class III PI3K. [29] [30] [31] Recently, it has also been shown that Rag proteins, which activate mTORC1 by inducing its physical interaction with Rheb, require amino acids for their action. 24 Apart from being a master regulator of translation, mTORC1 also controls transcription of genes involved in the control of cellular metabolism. For instance, mTORC1 activates both SREBP1 (sterol regulatory-binding protein 1) and PPARg (peroxisome proliferator-activated receptor-g), two transcription factors controlling the expression of genes involved in adipogenesis and lipid homeostasis. 24 Conversely, rapamycin treatment downregulates the expression of genes controlling lipid, protein and nucleotide synthesis, while upregulating genes involved in nutrient catabolism and energy production. 32 Interestingly, the mTOR kinase can also phosphorylate the signal transducer and activator of transcription 3 (STAT3), a transcription factor known to be a critical mediator of leptin's action on energy balance. 33 However, differently from leptin, which phosphorylates STAT3 on Tyr705, 34 mTOR phosphorylates the Ser727 residue. 35 This leads to STAT3 translocation in the mitochondria, where it increases oxidative phosphorylation. 36 Recent studies have actually started exploring the role of the mTORC1 pathway in mitochondria energy production, demonstrating that mTORC1 activation increases both oxygen consumption and mitochondrial number (reviewed in Finley and Haigis 37 ). In particular, it has been shown that mTORC1 controls mitochondrial oxidative function by positively regulating the activity of PGC1-a (PPARg coactivator 1), a nuclear cofactor that critically modulates mitochondrial biogenesis and oxidative metabolism. 38 Thus, mTORC1 might have a significant role in the coordination of cell growth and mitochondrial metabolism. However, in apparent contrast to these data, it has also been reported that NAD þ -dependent deacetylase sirtuin 1 (SIRT1), which controls mitochondrial number and fuel oxidation by activating PGC1-a, inhibits mTORC1 activity in a TSC2-dependent manner. 39 Although further work is required to clarify the role of the mTORC1 pathway in the regulation of mitochondrial function, these findings could be reconciled by taking into account the need for a context-specific regulation of mitochondrial substrate usage and activity. In fact, during cellular stress and energy depletion, anabolic and energy-consuming pathways like the mTORC1 cascade need to be turned off in favor of energy-producing processes. Accordingly, intracellular decrease in the ATP/adenosine monophosphate (AMP) ratio activates the AMP-activated protein kinase (AMPK), a master sensor of intracellular fuel status that, similar to SIRT1, is activated by states of negative cellular energy (reviewed in Hardie 40 ). Once activated, AMPK inhibits mTORC1 by phosphorylating TSC2 41 and by directly phosphorylating Raptor. 42 On the other hand, an increase in the ATP/AMP ratio directly activates the mTOR kinase, 20 while inhibiting AMPK (reviewed in Hardie 40 ). AMPK has been recently shown to mediate CNS actions of hormones and nutrients on food intake. 14, 43, 44 We will further illustrate in a following chapter the role of AMPK in energy balance and its relationship with mTORC1 in this context. Figure 1 schematically illustrates the regulation of mTORC1 signaling. For a more in-depth description of the intracellular signaling upstream and downstream of mTORC1, the reader should refer to recently published reviews. 19, 22, 24, 45 mTORC1 signaling and CNS regulation of energy balance
Within the CNS, the hypothalamus has recently emerged as a major center of convergence and integration of nutrient and hormonal cues, thus adjusting feeding behavior and peripheral metabolism in response to the fuel availability of the organism. In particular, the arcuate nucleus (ARC) of the hypothalamus has been the focus of intense research in the past few years, as two neuronal populations located in this area have been found to integrate the actions of hormonal and nutrient signals on energy balance. 7, 8, 10 Indeed, it is now well established that the activation of ARC neurons coexpressing the orexigenic neuropeptide Y and agoutirelated peptide stimulates food intake and increases body adiposity. [7] [8] [9] 46 Conversely, activation of ARC neurons producing pro-opiomelanocortin (POMC) and CART (cocaine-and amphetamine-regulated transcript) decreases food intake and body weight. [7] [8] [9] 46 Interestingly, although mTORC1 and its downstream targets, such as S6K1, are widely expressed throughout the brain, the phosphorylated forms of these kinases are specifically expressed in neuropeptide Y/agouti-related peptide and in POMC/CART neurons within the ARC of the rat hypothalamus. 16, 47 Moreover, phosphorylation levels of mTORC1, S6K1 and S6 are reduced in fasting, thus suggesting that ARC nutrient-sensing neurons use the pathway as a readout of the organism's energy status. 16 However, a recent neuro-anatomical study has further clarified that mTORC1 activity in the mediobasal hypothalamus (MBH) varies as a function of the cell type and of the particular stimulus used, as opposed to responding in a uniform manner to nutritional and hormonal changes. 48 As briefly mentioned before, insulin and leptin require an intact PI3K/Akt signaling in the ARC to reduce food intake. 25 The fact that mTORC1 is a downstream target of the PI3K/Akt pathway led us to hypothesize that hypothalamic mTORC1 signaling might be required for leptin-induced anorexia. Indeed, intracerebroventricular (i.c.v.) administration of leptin is associated with a time-dependent increase in the phosphorylation of both S6K1 and S6, whereas central administration of rapamycin prevents mTORC1 activation and leptin-induced anorexia. 16 Importantly, mice lacking S6K1 (S6K1 À/À ) are resistant to the anorectic action of mTORC1 and obesity C Catania et al leptin, 49 thus implying that S6K1 has a critical role in mediating leptin's action on energy balance. Accordingly, Blouet et al. 50 have recently demonstrated that adenovirusmediated constitutive activation of S6K1 in the rat MBH facilitates leptin-induced anorexia. In fact, MBH S6K1 activity is per se sufficient to decrease body weight, by primarily changing food intake through reduced neuropeptide Y and agouti-related peptide mRNA expression. 50 Moreover, bidirectional regulation of MBH S6K1 leads to complementary bidirectional changes in adaptive thermogenesis, thus suggesting that the hypothalamic S6K1 regulates the sympathetic drive to the brown adipose tissue (BAT). 50 Rats with constitutive activation of MBH S6K1 also seem protected against high-fat diet (HFD)-induced overeating and insulin resistance. 50 However, apparently in contrast with these findings, recent data also indicate that MBH S6K1 activity decreases MBH insulin signaling, an effect leading to hepatic insulin resistance. 51 This might suggest that within the MBH, intracellular pathways that regulate food intake and glucose homeostasis might diverge Figure 1 Regulation of the mTOR complex 1 (mTORC1) pathway. mTORC1 is composed of mTOR, Raptor, mLST8/GbL, PRAS40 and Deptor and can be activated by hormones, growth factors and nutrients. 19, 22, 24 Various upstream kinases (for example, ERK1/2, RSK1, PI3K/Akt, AMPK) that converge on the tuberous sclerosis complex (TSC1/TSC2), regulate mTORC1 activity. 19, 22, 24 Growth factors (for example, insulin) signal to mTORC1 through PI3K and Akt, which inactivates TSC2 to prevent TSC2 inhibition of mTORC1 through Rheb. 19, 22, 24 Activation of mTORC1 leads to phosphorylation of its downstream targets S6K1, 4E-BP1 and S6. 24 The mTOR complex 2 (mTORC2) is composed of mTOR, Rictor, mLST8/GâL, Deptor, protor-1 and SIN1. 22, 24 mTORC2 is known to activate Akt, thus facilitating activation of mTORC1. 27 Instead, low ATP levels lead to the AMPK-dependent activation of TSC2 to reduce mTORC1 signaling. 41 AMPK, which is activated by LKB1, also directly inhibits mTORC1 by phosphorylating Raptor. 42 Prolonged or constitutive activation of mTORC1/S6K1 signaling attenuates insulin-mediated PI3K/Akt activity by inhibition of IRS proteins. 19, 22, 24 Finally, amino acids increase mTORC1 signaling by favoring Rag protein action on mTORC1 and by inducing a Ca2 þ / calmodulin-mediated activation of hVPS34, a class III PI3K. 24, 29 4E-BP1, eukaryotic initiation factor 4E-binding protein; AMPK, adenosine monophosphate-activated protein kinase; Deptor, DEP-domain-containing mTOR-interacting protein; eEF2K eukaryotic elongation factor 2K; eIF4B and eIF4E, eukaryotic initiation factor 4B or 4E; ERK1/2, extracellular signal-regulated kinases1/2; GbL, G protein b-subunit-like protein; hVPS34, human vacuolar protein sorting-34; IRS, insulin receptor substrate; LKB1, liver kinase B1; mLST8, mammalian lethal with Sec13 protein 8; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide 3-kinase; PRAS40, proline-rich AKT substrate 40 kDa; Protor-1, protein observed with Rictor-1; Raptor, regulatory-associated protein of mTOR; Rheb, ras homolog enriched in the brain; Rictor, rapamycin-insensitive component of mTOR; RSK1, p90 ribosomal S6 kinase 1; S6, ribosomal protein S6; S6K1, ribosomal protein S6 kinase; SIN1, stressactivated protein kinase-interacting protein 1; TSC1/TSC2, tumor suppressor tuberosclerosis complex 1 and 2.
mTORC1 and obesity C Catania et al at the level of S6K1. Nevertheless, exposure to a HFD, even for a short period of time (24 h) dampens hypothalamic mTORC1 activity. 49 Under these conditions, leptin is unable to further modulate the pathway, thus implying that dysregulation of hypothalamic mTORC1 might represent one of the intracellular changes required for the onset of central leptin resistance. 49 Accordingly, the overexpression of SOCS 3 (suppressor of cytokine signaling 3, a negative regulator of leptin's action) within POMC neurons impairs both STAT3 and mTORC1 signaling before the onset of leptin resistance and obesity. 52 Differently from leptin, the cytokine ciliary neurotrophic factor reduces food intake and activates leptin-like pathways in the hypothalamus even in leptin-resistant states, including diet-induced obesity. 53 Under these conditions, i.c.v.
ciliary neurotrophic factor administration activates the hypothalamic mTORC1 pathway, although the appetitesuppressing action of ciliary neurotrophic factor critically depends on functional S6K1. 49 Hence, hypothalamic mTORC1 activity, although reduced by the exposure to a HFD, can be induced by ciliary neurotrophic factor treatment, thus suggesting that the pathway can still be appropriately modulated.
To regulate protein synthesis and cell growth, cells must integrate the information coming from hormonal signals together with those provided by nutrients. As such, the activity of the mTORC1 pathway is regulated not only by hormones but also by nutrients, particularly branched-chain amino acid. 28 Indeed, similar to leptin, i.c.v. administration of the branched-chain amino acid leucine phosphorylates hypothalamic S6K1 and S6, a phenomenon that critically mediates leucine-induced anorexia. 16 In fact, pretreatment with rapamycin (also given i.c.v.) blunts the anorectic effect of leucine. 16 Other studies have later confirmed the anorectic action of leucine, by administering the amino acid either directly into the brain, or peripherally, as a diet supplement. These reports further confirmed that leucine-induced anorexia is dependent on hypothalamic mTORC1 activity and associated with the inhibition of AMPK. 17, 18 Consistent with a cross-regulation between AMPK and mTORC1, the activation of these enzymes occurs in the same specific neuronal subtypes. 17 Furthermore, i.c.v. administration of leucine decreases mRNA levels of neuropeptide Y, [16] [17] [18] while increasing mRNA levels of POMC within the ARC.
17,18
Recently, Blouet et al. 54 have reported that intra-MBH administration of leucine reduces meal size and meal number by engaging a forebrain/hindbrain neurocircuit that activates ARC POMC neurons, paraventricular nucleus (PVN) oxytocin neurons and the nucleus of solitary tract neurons. Apart from S6K1, the authors have also identified the ERK1/2 pathway as a mediator of leucine's action on food intake. 54 However, the mechanism of leucine-induced ERK1/2 activation currently remains to be investigated. 54 As briefly stated above, AMPK and mTORC1 are oppositely regulated within the hypothalamus. Differently from mTORC1, hypothalamic AMPK is activated in response to signals of negative energy balance, such as food deprivation, low glucose levels and central administration of agoutirelated peptide or other orexigenic signals, such as ghrelin and cannabinoids. [55] [56] [57] Conversely, re-feeding, high glucose levels and central administration of leptin or insulin all reduce hypothalamic AMPK activity. 55 The mechanisms interfacing AMPK to the control of food intake are not yet completely understood and the reader is invited to refer to recent reviews that have extensively discussed this subject. 43, 44 Nevertheless, during the past few years, a clear association has been established between AMPK and CNS fatty acid metabolism in the context of energy balance regulation. For instance, it is known that AMPK hampers fatty acid synthesis by inhibiting acetyl-CoA carboxylase, the rate-limiting enzyme for the conversion of acetyl-CoA to malonyl-CoA, an intermediate of fatty acid synthesis, which is considered to work as a fuel-sensing signal within the hypothalamus. 58, 59 In relation to this, it has been shown that the orexigenic action of ghrelin depends on the activation of AMPK, resulting in decreased malonyl-CoA levels, increased fatty acid oxidation and recruitment of uncoupling protein 2 activity. 60, 61 Conversely, the ability of leptin to inhibit hypothalamic AMPK and to reduce food intake depends on acetyl-CoA carboxylase activation and increased malonyl-CoA levels. 62 The intracellular increase in malonyl-CoA levels is predicted to be associated with increased glucose oxidation as a consequence of decreasing fatty acid oxidation. In 2003, Wortman et al. 63 proposed that the relative ratio of glucose to fatty acid utilization in the hypothalamus is an index of the overall energy status of the body, which is monitored by neurons and used to regulate food intake. Inhibitors of the fatty acid synthase, the enzyme regulating the use of malonyl-CoA for the synthesis of fatty acids, potently reduce food intake when administered either centrally or peripherally. 59, 64 However, and in agreement with the hypothesis postulated by Wortman et al., 63 when animals become ketotic and use ketones instead of glucose for their energetic needs, i.c.v. administration of fatty acid synthase inhibitors does not affect food intake. 65 Importantly, fatty acid synthase inhibitors reduce food intake by inducing hypothalamic mTORC1 activity. During ketosis, central administration of fatty acid synthase inhibitors not only does not decrease food intake but is also unable to induce hypothalamic mTORC1 activity, thus implying that the ability of this class of compounds to modulate mTORC1 signaling might depend on glucose presence and/or utilization. 65 A great part of the studies investigating the role of fuelsensing mechanisms in energy balance has so far focused on the role of such mechanisms in the hypothalamus. However, recent work has started to explore intracellular fuel-sensing also in those brain areas known to control reward and motivation, which critically affect the decision about whether to eat. 11, 12 For instance, it has been shown that leptin modulates reward by acting on the ventral tegmental mTORC1 and obesity C Catania et al area and the nucleus accumbens, where it engages the same intracellular pathways (STAT3, PI3K) known to mediate its anorectic actions in the hypothalamus. [66] [67] [68] Interestingly, leptin's effects in the ventral tegmental area seem to be required for its ability to reduce food intake and body weight. 67, 69 However, activation of PI3K and mTORC1
within the ventral tegmental area is not necessary for ventral tegmental area-mediated leptin anorexia. 69 Finally, although out of the scope of this review, it is worth highlighting that mTORC1 activity within the CNS is not only directly involved in the regulation of energy balance, but might have a role in the regulation of neuroendocrine axes, such as the gonadotropic axis 70 and in the circadian clock entrainment process. 71 Owing to its critical intracellular function, mTORC1 is also required for the modulation of essential neuronal functions, including axon guidance, dendrite development, dendritic spine morphogenesis and synaptic plasticity. 72, 73 A recent study by Mori et al. has actually underscored the impact of mTORC1-dependent neuronal functions on energy balance regulation. The authors genetically induced mTORC1 overactivity by deleting TSC1 in ARC POMC neurons. Differently from the initial expectation, the resulted phenotype was characterized by hyperphagia and obesity, because overactivity of mTORC1 induced profound alterations in the morphology of POMC neurons, leading to cellular hypertrophy and a decrease in neuronal projections. 74 Thus, although further studies are required, it seems reasonable to suggest that mTORC1 signaling might affect feeding behavior by modulating dendrite morphology and synaptic activity of those neuronal circuits known to have a role in the regulation of energy balance.
mTORC1 signaling and the regulation of peripheral metabolism
The regulation of energy balance by mTORC1 is likely due to the coordination of metabolic processes in different organs. The mTORC1 pathway is clearly present in every organ, where it displays tissue-specific functions. Thus, apart from its role in the CNS and particularly the hypothalamus, it would be appropriate at this point to briefly mention its function in metabolically relevant tissues, such as the skeletal muscle, the adipose tissue, the pancreas and the liver. Table 1 summarizes the physiological functions of the mTORC1 pathway in the different organs.
mTORC1 in the muscle mTORC1 is arguably one of the most important nutrientregulated intracellular signaling pathways in the muscle. It is responsible for protein synthesis in the muscle tissue, where it is activated through nutrients, insulin, growth factors and exercise. 75 Recent studies have shown that the mTORC1 component Raptor is required for oxidative muscle integrity, whereas Rictor is dispensable. 76 Furthermore, muscle-specific inactivation of mTOR leads to severe myopathy, resulting in premature death. 77 Both Raptor and mTOR deficiency in the muscle result in metabolic changes, including impaired oxidative metabolism, altered mitochondrial regulation and glycogen accumulation, which lead to a dystrophic phenotype. 76, 77 Notably, S6K1 regulates muscle cell size through inhibition of AMPK. 78 Endurance-and resistance-type exercises are known to enhance insulin sensitivity and lead to specific structural adaptations in the skeletal muscle. 79 In particular, mTORC1
signaling is increased following both aerobic endurance and heavy resistance exercise. 79 In contrast, rapamycin treatment reduces muscle hypertrophy in animal models and in muscle cell lines (reviewed in the studies by Hornberger and Chien 75 , and Rivas et al.
79
). Nevertheless, our knowledge on how muscle contraction might lead to mTORC1 activation is at present very limited.
Besides the activation of mTORC1 through exercise, also nutrients modulate mTORC1 activity in the muscle. Branched-chain amino acid and leucine in particular are as effective as a complete meal in stimulating mRNA translation initiation in the muscle by specifically targeting the mTORC1 pathway. 28 This notion has led to several investigations focusing on the potential ability of amino acids to work as specific nutrients able to counteract protein wasting occurring in diseases, such as cancer, HIV infection and sepsis, and to help maintain muscle mass in the elderly.
Available evidence also supports a role for the mTORC1 pathway in muscle glucose uptake and insulin sensitivity. 79, 80 In particular, mTORC1 may alter insulin action in response to chronic increase of fatty acid availability. 79 In fact, S6K1 phosphorylation is increased in the skeletal muscle of diet-induced obese rats and this is in turn associated with elevated inhibitory phosphorylation of IRS1 and insulin resistance. 81 Conversely, S6K1 À/À mice show enhanced insulin sensitivity under HFD, which is accompanied by reduced IRS1 phosphorylation in the skeletal muscle.
82 Table 1 The physiological function of the mTORC1 pathway in different organs and tissues
Tissue Physiological function
Hypothalamus Regulation of food intake and body weight; transduction of hormonal and nutrient signals; possible involvement in the modulation of the sympathetic tone [16] [17] [18] 49, 50, 54, 65, 112 Muscle Maintenance of muscle mass; regulation of muscle cell size; regulation of muscle oxidative metabolism 28, [75] [76] [77] [78] [79] Adipose tissue Differentiation and maintenance of white adipocytes [88] [89] [90] [91] Pancreas Regulation of b-cell mass; regulation of glucose-stimulated insulin secretion [95] [96] [97] [98] [99] [100] [101] [102] [103] Liver Regulation of hepatocytes growth and lipid metabolism [104] [105] [106] [107] [108] [109] Abbreviation: mTORC1, mammalian target of rapamycin complex 1.
mTORC1 and obesity C Catania et al mTORC1 in the adipose tissue The white adipose tissue (WAT) is the body long-term fat storage as well as an important endocrine organ that secretes cytokines and hormones, such as leptin, adiponectin, resistin and many others. 83, 84 These hormones have critical roles in the regulation of energy balance, lipid metabolism, fertility, immune and stress responses. 83, 84 Moreover, an excess or deficiency of WAT can lead to severe metabolic diseases, such as diabetes, cardiovascular disorders and cancer. 83, 84 In contrast, the BAT principally affects energy homeostasis through adaptive thermogenesis. 85 For this purpose, the BAT oxidizes fatty acids and dissipates the energy as heat. BATmediated heat production requires activation of the uncoupling protein 1, which uncouples the mitochondrial proton gradient that is generated by the respiratory chain. 85 Upregulation of uncoupling protein 1 by genetic manipulations or pharmacological agents can facilitate weight loss and improve insulin sensitivity. 86, 87 Moreover, trans-differentiation between the WAT and the BAT can be potentially beneficial for the treatment of obesity. 86 This process can be achieved by modulating the expression of transcription factors, such as PRDM16 (PRD1-BF1-RIZ1 homologous domain containing 16), PGC1-a, RIP140 (receptor-interacting protein of 140 kDa) and others. 85, 87 In vitro experiments have demonstrated that mTORC1 is essential for the differentiation and maintenance of white adipocytes. Indeed, mTORC1 activation is necessary for insulin-or nutrient (amino acid)-induced adipogenesis and expression of SREBP1 and PPARg, which are master transcriptional regulators of adipocyte differentiation and lipid homeostasis. [88] [89] [90] Conversely, rapamycin impairs adipocyte differentiation by inhibiting PPARg transactivation activity. 88 Interestingly, leptin synthesis in the mature white adipocyte is also dependent on mTORC1 91 and, as suggested by
Maya-Monteiro and Bozza, 92 mTORC1 could provide a positive feedback mechanism for the action of leptin on white adipocytes. On the other hand, full brown adipocyte differentiation requires AMPK activation associated with mTORC1 inhibition, although mTORC1 activation is essential during the first stages of differentiation. 93 The use of transgenic mice has recently allowed further dissecting the role of mTORC1 signaling in the adipose tissue. By specifically knocking out Raptor in the WAT, Polak et al. 94 have demonstrated that the obtained conditional knockout mouse is resistant to diet-induced obesity because of elevated energy expenditure. The increase in energy expenditure is caused by enhanced mitochondrial respiration and uncoupling protein 1 expression in the WAT. 94 Thus, lack of Raptor in WAT leads to BAT transdifferentiation; hence, indirectly confirming the negative role of the mTORC1 pathway in the induction of the brown adipocyte phenotype.
93
In diet-induced obesity, overactivity of the mTORC1 signaling favors the expansion of the WAT mass, leading to adipocytes insulin resistance through elevated phosphorylation of IRS1. 82 mTORC1 in endocrine pancreas Taking into account its role as a nutrient sensor, mTORC1 is undoubtedly an important hub for signals that regulate the b-cell response to nutrients. As such, mTORC1 signaling is a positive regulator of b-cell mass and favors b-cell proliferation and insulin synthesis. 95 In fact, reduced islet size, glucose intolerance and hypoinsulinemia have been described in chow-fed S6K1 À/À mice, 96 as well as in mice deficient for its direct substrate S6. 97 As already reported for the muscle, in vitro studies demonstrating the ability of activated mTORC1/S6K1 to inhibit insulin signaling in b-cell led to the conclusion that the inhibition of the pathway would improve insulin sensitivity and ameliorate b-cell performance in diet-induced obesity and type 2 diabetes. 95 However, recent evidence collected from pharmacological studies with rapamycin and from the use of transgenic mice lacking components of the mTORC1 pathway specifically in b-cell has identified mTORC1 signaling as a positive, critical mediator of the b-cell adaptation to chronic nutrient overload and increased insulin demand in type 2 diabetes. Indeed, in vivo overactivity of mTORC1 signaling, due to deletion of either TSC2 (a negative regulator of mTORC1) or loss of LKB1 (a positive regulator of AMPK) in b-cells, increases b-cell mass and improves glucose tolerance. 98, 99 Conversely, rapamycin treatment leads to inhibition of b-cell proliferation and apoptosis, 100, 101 and worsens hyperglycemia in obese animals by inhibiting glucose-stimulated insulin secretion. 102, 103 mTORC1 in the liver As expected, once activated, mTORC1 signaling has a positive effect on hepatocyte growth, protein synthesis and cell cycle, and hence contributes to liver regeneration. 104 Furthermore, and as already reported for other tissues, either amino acids or insulin can stimulate hepatic mTORC1 signaling. 105 Notably, data collected from transplant and cancer patients, as well as from animal models chronically treated with rapamycin suggest a role for the mTORC1 pathway in hepatic lipid metabolism. Indeed, rapamycin treatment alters triglyceride metabolism by increasing circulating both very low-density lipoproteins and low-density lipoproteins. [106] [107] [108] However, the hyperlipidemia observed with the drug in vivo is likely due to delayed peripheral clearance rather than enhanced hepatic synthesis. In fact, rapamycintreated hepatocytes show increased fatty acid oxidation and concomitant reduction in de novo lipid synthesis. 109 On the other side, non-alcoholic fatty liver disease, which is characterized by fat accumulation in the liver and is commonly observed in obese subjects, is associated with increased hepatic mTORC1 phosphorylation and, possibly, with increased SREBP1 expression (reviewed in the study by Laplante and Sabatini 88 ). As previously reported for the muscle and the WAT, increased mTORC1/S6K1 activity in mTORC1 and obesity C Catania et al the liver of diet-induced obese rodents leads to phosphorylation of IRS1 and consequently to hepatic insulin resistance.
81
mTORC1 signaling in metabolic disease: potential target for therapy?
Recent evidence that we have reviewed in the previous chapters implicates the mTORC1 pathway as a key cellular fuel sensor the activity of which, particularly within the MBH, decreases food intake in response to both nutrient and hormonal signals. Conversely, in peripheral tissues, the pathway exerts an anabolic role, favoring glucose uptake, adipogenesis and lipid biosynthesis (see also Table 1 ). These seemingly opposite functions are in agreement with the ability of the mTORC1 signaling cascade to work as an intracellular sensor of energy surfeit, and reconcile with its role as insulin's downstream target. During exposure to a HFD, the hypothalamic circuitry becomes susceptible to hormonal and nutrient resistance, which in turn can predispose to hyperphagia, weight gain and altered glucose homeostasis. Recent studies have shown that hypothalamic mTORC1 signaling is critically involved in the development of this central resistance, 49, 50, 52 although future investigations will need to address the actual molecular, electrophysiological and structural events underlying this phenomenon. Nevertheless, although the pathway seems to have a protective role within the hypothalamus during diet-induced obesity, its chronic activation in peripheral tissues has been identified to be detrimental and associated with insulin resistance. However, recently published evidence has actually demonstrated that, contrary to what was expected, pharmacological inhibition of the pathway worsens insulin resistance and diabetes in diet-induced obese animal models. 102, 103 This is due to the induction of b-cell apoptosis 100, 101 and that of increased hepatic gluconeogenesis caused by chronic (at least 2 weeks) and systemic treatment with rapamycin. 110 Hence, mTORC1
signaling is actually a critical mediator of cellular adaptation to nutrient overload and increased insulin demand during diet-induced obesity, which is a conclusion further confirmed by genetically inducing mTORC1 overactivity within b-cells. 98, 99, 111 Nevertheless, these recent published data also highlight how much remains to be done to better understand the role of the mTORC1 pathway in the physiopathology of obesity and other metabolic diseases. The evidence reported so far clearly suggests that it might be counterproductive to broadly target the mTORC1 pathway for the treatment of obesity and obesity-related metabolic alterations, such as hyperlipidemia, glucose intolerance and insulin resistance. This is due to the critical participation of the pathway in several aspects of energy balance regulation, from energy intake to energy storage and maintenance of appropriate intracellular responses to nutrient surfeit. 
Conclusions
Considering the urgency that modern societies face in efficiently tackling obesity and type 2 diabetes, intense research is required to understand the biological mechanisms underlying the regulation of energy balance and peripheral metabolism. Recent work carried out by others and by us has demonstrated the role of the evolutionarily conserved mTORC1 pathway in critically integrating hormonal and nutrients signals that affect hypothalamic circuits controlling energy balance. In peripheral, metabolically relevant tissues, the mTORC1 pathway has important functions, ranging from modulation of oxidative metabolism in the muscle, to WAT differentiation and b-cell dependent insulin secretion (see Figure 2) . During dietinduced obesity, the downregulation of the pathway in hypothalamic circuits and its overactivity in peripheral tissues reflect intracellular metabolic adaptations observed in response to increased circulating insulin, leptin and nutrient levels (see Figure 2) . Nonetheless, it is clear that we are just beginning to appreciate the complexity of the mTOR network and its role in the regulation of cellular physiology. In particular, defining the functions of specific mTORC1 downstream targets and clarifying the still underinvestigated role of mTORC2 in the context of cellular metabolism will be essential steps towards a better understanding of the role of the mTOR pathway as a potential therapeutic target for the treatment of obesity and other metabolic disorders.
Conflict of interest
The authors declare no conflict of interest.
